[Anti-centromere antibody, biological marker of the CREST syndrome as distinct from scleroderma].
Using HEp2 cells to study antinuclear antibodies has resulted in the discovery of the anti-centromere antibody which is thought to separate the CREST syndrome from progressive systemic sclerosis (scleroderma). This antibody seems to be exceptional in healthy subjects and are in patients with connective tissue diseases, except for scleroderma. It has also been found in CREST syndrome associated with other diseases, such as primary cirrhosis and neoplasias. In our study, the sensitivity of the anti-centromere antibody was 89.1% and its specificity 92.3% which shows that it is worth looking for.
Rouquette-Gally
A M
AM
Stern
M H
MH
Prost
A C
AC
Abuaf
N
N
Homberg
J C
JC
Combrisson
A
A
D000328:Adult; D000368:Aged; D000818:Animals; D000974:Antibodies, Antinuclear / Q000032:analysis*; D002114:Calcinosis / Q000276:immunology; D002503:Centromere / Q000276:immunology*; D002875:Chromosomes / Q000276:immunology*; D003240:Connective Tissue Diseases / Q000276:immunology; D003937:Diagnosis, Differential; D005260:Female; D005385:Fingers; D006801:Humans; D008297:Male; D008875:Middle Aged; D051381:Rats; D011928:Raynaud Disease / Q000276:immunology*; D012595:Scleroderma, Systemic / Q000276:immunology*; D013577:Syndrome; D013684:Telangiectasis / Q000276:immunology*
D000974:Antibodies, Antinuclear
L'anticorps anticentromère, marqueur biologique de la variété CREST de la sclérodermie.